Growing the love for investing
Results 81 - 90 of 757 : Previous 5 6 7 8 9 10 11 12 13 Next
1 Reason the Street Should Love Gilead Sciences' Earnings
Don’t just count the cash, time it.
Here's one of Buffett's favorite metrics for evaluating companies.
Generics are a bigger threat than Sangamo for now.
One Step Closer to an FDA Decision
Cell Therapeutics is still risky, though.
Will Gilead Sciences Blow It Next Quarter?
Look here for a clue.
Here's How Amgen Is Making You So Much Cash
All cash flow is not created equal.
Disc throws and midnight buffets played more than a bit part this week.
How Long Does It Take to Make a Buck at Biogen Idec?
Don't just count the cash, time it.
Phase 3 + Phase 3 = Quad Approval
But will Gilead Sciences' new four-drug cocktail sell?
Look here for a clue.
Results 81 - 90 of 757 : Previous 5 6 7 8 9 10 11 12 13 Next
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK